Newborn Respiratory Distress Syndrome

A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.

Also Known As:

Networked: 660 relevant articles (46 outcomes, 98 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
2.	Premature Birth (Birth, Premature)
3.	Birth Weight (Birth Weights)
4.	Bronchopulmonary Dysplasia
5.	Perinatal Death

Experts

1.	Hamvas, Aaron: 11 articles (01/2021 - 10/2006)
2.	Cole, F Sessions: 8 articles (11/2016 - 10/2006)
3.	Wegner, Daniel J: 7 articles (11/2016 - 08/2007)
4.	Soll, R F: 7 articles (07/2007 - 01/2000)
5.	Salomone, Fabrizio: 6 articles (06/2022 - 01/2017)
6.	Haas, David M: 6 articles (06/2021 - 05/2012)
7.	Speer, Christian P: 6 articles (01/2021 - 01/2011)
8.	Dalziel, Stuart R: 6 articles (08/2007 - 09/2004)
9.	Harding, Jane E: 6 articles (08/2007 - 09/2004)
10.	Parag, Varsha: 6 articles (08/2007 - 09/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Newborn Respiratory Distress Syndrome:

1.	Surface-Active Agents (Surfactants)IBA 01/01/2020 - "Surfactant treatment for neonatal respiratory distress syndrome has dramatically improved survival of preterm infants. " 10/01/2008 - "Since the widespread use of exogenous lung surfactant to treat neonatal respiratory distress syndrome, premature infant survival and respiratory morbidity have dramatically improved. " 01/01/1992 - "Randomized trials have proven that exogenous surfactant is effective in severe neonatal respiratory distress syndrome when strict entry criteria are applied. " 07/01/1998 - "The method of surfactant instillation into the lungs for treatment of neonatal respiratory distress syndrome is an important attribute of delivery, and it may determine the overall efficacy of treatment. " 01/01/2005 - "Exogenous surfactants have been used as an effective treatment of neonatal respiratory distress syndrome (RDS). "
2.	Pulmonary Surfactants (Pulmonary Surfactant)IBA 08/12/2022 - "To investigate the efficacy of high-frequency oscillatory ventilation (HFOV) combined with pulmonary surfactant (PS) in the treatment of neonatal respiratory distress syndrome (NRDS). " 04/01/1989 - "Pulmonary surfactant replacement has previously been shown to be effective in the human neonatal respiratory distress syndrome. " 05/02/2020 - "[Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: a multicenter clinical trial]." 04/01/2012 - "[Comparisons of efficacy of different pulmonary surfactants for the treatment of neonatal respiratory distress syndrome]." 11/25/2020 - "Pulmonary surfactant (PS) is commonly used for the treatment of neonatal respiratory distress syndrome (NRDS), several randomized controlled trials (RCTs) have evaluated the role of nebulized versus invasively delivered PS, yet the results remained inconsistent. "
3.	beractant (Survanta)FDA Link 01/01/2021 - "Aerosolized Beractant in neonatal respiratory distress syndrome: A randomized fixed-dose parallel-arm phase II trial." 03/01/1993 - "A multicenter, randomized, double-blind, controlled trial compared three beractant (Survanta) administration procedures in the treatment of neonatal respiratory distress syndrome. " 04/01/2008 - "Moreover, the data obtained were compared with those of commercially available Surfacten (Surfactant TA) which has been clinically used for neonatal respiratory distress syndrome (NRDS) in Japan. " 08/01/1998 - "The mixtures were prepared by adding serial dilutions of human meconium to various concentrations of Surfactant-TA (Surfacten) that had been used for the prevention and treatment of neonatal respiratory distress syndrome. " 06/01/1994 - "In 1988 and 1989, a total of 1228 infants were studied in four double-blind, controlled, multidose clinical trials establishing the safety and efficacy of beractant (Survanta intratracheal suspension, Ross Products Division of Abbott Laboratories), a modified bovine lung extract, in prevention and treatment of neonatal respiratory distress syndrome in premature infants. "
4.	Ambroxol (Mucosolvan)IBA 05/01/1997 - "This study does not suggest the efficacy of antenatal ambroxol treatment both for the prevention of neonatal respiratory distress syndrome and for the reduction of its severity." 09/01/2009 - "[Efficacy of different dosages of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome]." 10/31/2014 - "Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome." 07/01/2019 - "Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome." 02/01/1986 - "The results of this study indicate that Ambroxol compared to Betamethasone can be considered as an effective drug for prevention of neonatal respiratory distress syndrome."
5.	tyloxapol drug combination hexadecanol dipalmitoylphosphatidylcholine (Exosurf Neonatal)FDA Link 11/01/1991 - "A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome." 06/01/1997 - "Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome." 01/01/1996 - "To compare the efficacy of a synthetic surfactant (Exosurf Neonatal, Burroughs-Wellcome Co) and a modified bovine surfactant extract (Survanta, Ross Laboratories) in the treatment of neonatal respiratory distress syndrome (RDS). " 11/01/1993 - "To compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome. " 05/01/1999 - "This study compares the effects of synthetic (Exosurf) and natural (Survanta) surfactants on infants with neonatal respiratory distress syndrome in Oman. "
6.	poractant alfa (Curosurf)FDA Link 01/01/2022 - "Non-invasive administration of poractant-α in neonatal respiratory distress syndrome via a supraglottic device in the clinical practice in a second level neonatal unit: comparison of LMA® vs iGel® devices." 01/01/1990 - "European multicenter trials of curosurf for treatment of neonatal respiratory distress syndrome." 09/01/1994 - "A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome." 01/01/2020 - "Aim: To evaluate the effect of the initial dose of poractant alfa on clinical outcomes in neonatal respiratory distress syndrome (RDS) and to assess adherence to treatment guidelines recommending a dose of 200 mg/kg. Methods: Records of neonates who received poractant alfa with a less invasive technique (LISA) or with the INtubate-SURfactant-Extubate (INSURE) technique were retrieved from the aggregated datasets of three prospective RDS studies conducted between 2015 and 2019. " 06/01/2005 - "A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome."
7.	Ritodrine (Yutopar)FDA Link 09/01/1990 - "We retrospectively studied 209 patients treated with ritodrine hydrochloride to determine whether change in cervical effacement or dilatation during a period of observation before therapy would result in decreased efficacy of ritodrine, as measured by delivery delays of 48 hours, 1 week, or until greater than or equal to 37 weeks' gestation; neonatal intensive care unit admission; and neonatal respiratory distress syndrome. " 08/01/1987 - "We speculate that preferential beta-2 adrenergic stimulation of the fetal lung with ritodrine could be helpful in the prevention of neonatal respiratory distress syndrome because of enhanced surfactant availability in airways and improved pulmonary mechanics."
8.	Dexamethasone (Maxidex)FDA LinkGeneric 11/01/1998 - "The study's objective was to compare the efficacies of oral and intramuscular antenatal administration of dexamethasone in reducing neonatal respiratory distress syndrome. " 10/01/1981 - "A double-blind, collaborative, randomized trial was initiated in 1976 to evaluate dexamethasone administered to mothers as a method of preventing neonatal respiratory distress syndrome (RDS). " 09/15/1980 - "A trial of intravenous dexamethasone for prevention of neonatal respiratory distress syndrome was carried out prospectively. " 01/01/2022 - "Dexamethasone has been widely used in clinical practice to promote fetal lung maturity and reduce neonatal respiratory distress syndrome and perinatal mortality. " 11/01/1998 - "A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome."
9.	Proteins (Proteins, Gene)FDA Link 09/01/1992 - "The preterm ventilated lung is characterized by an increased protein leak from the pulmonary vascular spaces into the air spaces, which interferes with lung function and plays a role in neonatal respiratory distress syndrome. " 01/01/2017 - "The aim of this pilot study was to determine Clara cell protein (CC16) concentration in bronchoalveolar lavages (BAL) fluid from full-term and preterm (<37 weeks' gestational age) neonates requiring respiratory support, having symptoms of neonatal respiratory distress syndrome, and at risk of bronchopulmonary dysplasia (BPD). " 11/01/2000 - "Surfactant proteins A and B as interactive genetic determinants of neonatal respiratory distress syndrome." 09/01/1992 - "Platelet-activating factor plays a role in the protein leak seen in the preterm lung, which contributes to neonatal respiratory distress syndrome." 07/01/1983 - "These results suggest that protein concentrations in surfactant mixtures can be minimized for applications such as exogenous lung surfactant replacement for the neonatal Respiratory Distress Syndrome (RDS). "
10.	SteroidsIBA 04/01/2007 - "Randomized controlled trials are needed to determine the optimal number of courses of antenatal steroids to reduce the frequency of neonatal respiratory distress syndrome (RDS) without adversely affecting other neonatal outcomes." 01/01/2005 - "Does smoking in pregnancy modify the impact of antenatal steroids on neonatal respiratory distress syndrome? " 04/01/2008 - "Maternal steroid injections shortly before premature delivery reduce the risk of neonatal respiratory distress syndrome. " 01/01/2017 - "Although antenatal steroids and early use nasal continuous positive airway pressure (NCPAP) have significantly improved outcomes of neonatal respiratory distress syndrome, intubation with ventilator support is still commonly required in extremely low birth weight (ELBW) infants. " 01/01/2005 - "To assess the relation between cigarette smoking during pregnancy and neonatal respiratory distress syndrome (RDS) in very preterm birth, and to analyse the differential effect of antenatal steroids on RDS among smokers and non-smokers. "

Therapies and Procedures

1.	Therapeutics 03/01/1987 - "The incidence of neonatal respiratory distress syndrome was extremely high, 12 milder cases could be managed without ventilation therapy, 4 severe cases had to be given full respiratory support." 01/01/1994 - "PLV, a potential therapy for adult and neonatal respiratory distress syndrome (RDS), is conventional mechanical ventilation (CMV) with the lung filled to about functional residual capacity with perfluorochemical liquid. " 12/14/2014 - "Surfactant replacement therapy has been proven beneficial in the prevention and treatment of neonatal respiratory distress syndrome (RDS). " 07/18/2007 - "Surfactant replacement therapy has been proven beneficial in the prevention and treatment of neonatal respiratory distress syndrome (RDS). " 05/01/2015 - "Deficiencies of surfactant components are classically observed in the neonatal respiratory distress syndrome, where surfactant replacement therapies have been the mainstay of treatment. "
2.	Artificial Respiration (Mechanical Ventilation) 12/01/2023 - "Mechanical ventilation, as a critical breathing support, plays a critical role in the treatment of neonatal respiratory distress syndrome (NRDS). " 01/01/2021 - "Objective: To investigate the predictive value of lung ultrasound score (LUS) in the extubation failure from mechanical ventilation (MV) among premature infants with neonatal respiratory distress syndrome (RDS). " 01/01/2021 - "Roles of Lung Ultrasound Score in the Extubation Failure From Mechanical Ventilation Among Premature Infants With Neonatal Respiratory Distress Syndrome." 01/01/2019 - "Mechanical Ventilation in Neonatal Respiratory Distress Syndrome at High Altitude: A Retrospective Study From Tibet." 01/01/2000 - "Neutrophil counts were studied in 62 preterm infants receiving mechanical ventilation for neonatal respiratory distress syndrome (NRDS). "
3.	Continuous Positive Airway Pressure 06/01/2018 - "To study the clinical effect and safety of bubble nasal continuous positive airway pressure (BNCPAP) versus conventional nasal continuous positive airway pressure (nCPAP) in respiratory support for preterm infants with neonatal respiratory distress syndrome (NRDS). " 01/01/2020 - "Background/Aims: Nasal continuous positive airway pressure (nCPAP) was recommended as the initial respiratory support for spontaneous breathing in infants with very low birth weight and neonatal respiratory distress syndrome (NRDS). " 01/01/2020 - "Nasal continuous positive airway pressure support (nCPAP) is the standard of care for prematurely born infants at risk of neonatal respiratory distress syndrome (nRDS). " 06/01/2018 - "[Clinical effect of bubble nasal continuous positive airway pressure versus conventional nasal continuous positive airway pressure in respiratory support for preterm infants with neonatal respiratory distress syndrome]." 02/01/2014 - "Management of Neonatal Respiratory Distress Syndrome Employing ACoRN Respiratory Sequence Protocol versus Early Nasal Continuous Positive Airway Pressure Protocol."
4.	Length of Stay 10/01/2018 - "After adjustment for covariates, a higher maternal n6:n3 FA ratio was associated with impaired fetal growth (birth-weight-for-gestational-age z score, β = -0.04 per unit increase in n6:n3; 95% CI, -0.07 to -0.01), 1day shorter length of gestation (β = -0.14 week; 95% CI, -0.27 to -0.01), higher incidence of neonatal respiratory distress syndrome (odds ratio, 1.37; 95% CI, 1.04 to 1.80), and increased length of neonatal hospital stay (β = 0.29 day; 95% CI, 0.003 to 0.58) in OWOB, but not lean, participants. " 01/01/2008 - "The newborns in the assisted group had more complications than the spontaneous group; most notable were respiratory distress syndrome, newborn intensive care admission, sepsis, and longer hospital stay (4.8 days vs. 1.6 days, P < 0.001). " 02/01/2007 - "The newborns in the assisted group had more complications than the spontaneous group; most notable were respiratory distress syndrome, newborn intensive care admission, infection and longer hospital stay (6 days vs 15 days, P < 0.001). " 10/07/2009 - "However, no statistically significant reduction was found in the incidence of neonatal respiratory distress syndrome (RR 0.32; 95% CI 0.07 to 1.58), transient tachypnoea of the newborn (RR 0.52; 95% CI 0.25 to 1.11), need for mechanical ventilation (RR 4.07; 95% CI 0.46 to 36.27) and length of stay in neonatal intensive care unit (MD) -2.14 days; 95% CI -5.58 to 1.30).There were no reported events of neonatal sepsis, perinatal deaths or maternal trauma infection, therefore results on these outcomes are non-estimable. " 05/01/2014 - "Adding metformin to insulin therapy in women with insulin-resistant diabetes mellitus with pregnancy seems to be effective in proper glycemic control in a considerable proportion of women, along with benefits of reduced hospital stay, reduced frequency of maternal hypoglycemia as well as reduced frequency of neonatal hypoglycemia, NICU admission and neonatal respiratory distress syndrome."
5.	Mechanical Ventilators (Ventilator) 02/01/2022 - "Outcomes of interest included neonatal intensive care unit (NICU) admission, neonatal respiratory distress syndrome (NRDS), ventilator support and a composite outcome combining major morbidities and neonatal death. " 01/01/2021 - "There were no differences between IVF/ICSI and spontaneous DCDA pregnancies in terms of spontaneous preterm birth, gestational diabetes mellitus, pregnancy-induced hypertensive disorder, preeclampsia, intrahepatic cholestasis of pregnancy, placenta previa, birthweight discordance, small for gestational age, neonatal respiratory distress syndrome, ventilator support, and perinatal death and/or severe morbidity. " 01/01/2021 - "The primary outcome of interest was preterm birth <37 weeks of gestation and secondary outcomes included spontaneous preterm birth, iatrogenic (induced) preterm birth, gestational diabetes mellitus, pregnancy-induced hypertensive disorder, preeclampsia, preterm premature rupture of membranes (PPROM), intrahepatic cholestasis of pregnancy, placenta previa, neonatal intensive care unit (NICU) admission, birthweight discordance, small for gestational age, neonatal respiratory distress syndrome, ventilator support, and perinatal death and/or severe morbidity. " 08/12/2022 - "The effect of high-frequency oscillatory ventilator combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome." 01/01/2017 - "Although antenatal steroids and early use nasal continuous positive airway pressure (NCPAP) have significantly improved outcomes of neonatal respiratory distress syndrome, intubation with ventilator support is still commonly required in extremely low birth weight (ELBW) infants. "